Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years
Patrick R. Funk, Osman N. Yoğurtçu, Richard A. Forshee, S.A. Anderson, Peter Marks, Hong Yang
Topics & Concepts
MedicineVaccinationCoronavirus disease 2019 (COVID-19)PandemicMyocarditisYoung adultPediatricsDemographyEmergency medicineInternal medicineImmunologyDiseaseInfectious disease (medical specialty)SociologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Immunology Research